|Title:||Oral osmotic system for slightly soluble active agents|
|Abstract:||An oral sustained release composition for slightly soluble pharmaceutically active agents comprising a core, a wall around said core, and a bore through said wall connecting said core and the environment outside of said wall; wherein said core comprises a slightly soluble active agent, optionally a crystal habit modifier, at least two osmotic driving agents, at least two different (or two different grades of) hydroxyalkyl celluloses, and optionally lubricants, wetting agents, and carriers; said wall being substantially impermeable to said core components and permeable to water and gastro-intestinal fluids. The composition is most especially adapted for administering carbamazepine.|
|Inventor(s):||Koparkar; Arun D. (Westfield, NJ), Shah; Shailesh B. (Union, NJ)|
|Assignee:||Ciba-Geigy Corp. (Ardsley, NY)|
1. An oral osmotic dosage delivery form adapted to deliver carbamazepine comprising
(a) core comprising
i. carbamazepine in an amount sufficient to deliver an effective amount thereof over the intended delivery time;
ii. an effective amount of a crystal habit modifier for said carbamazepine selected from the group consisting of C.sub.1-4 alkyl cellulose, hydroxypropyl cellulose, hydroxypropyl-C.sub.1-4 alkyl cellulose, sodium carboxymethyl cellulose, sodium carboxymethyl-C.sub.1-4 alkylcellulose, and gelatin;
iii. from about 2% to about 15% of the total core weight of a mixture of at least two different hydroxy-C.sub.1 -C.sub.4 alkyl celluloses which may be hydroxyalkyl celluloses having different alkyl groups or hydroxyalkyl celluloses having the same alkyl groups but are of different grades, wherein the ratio of the higher viscosity hydroxy-C.sub.1 -C.sub.4 alkyl cellulose to the lower viscosity hydroxy-C.sub.1 -C.sub.4 alkyl cellulose is about 2:1;
iv. a C.sub.6 sugar alcohol;
v. a mono- or di-saccharide;
vi. from 0 to an effective amount of a tabletting lubricant; and
vii. from 0 to an effective amount of a wetting agent;
said C.sub.6 sugar alcohol and said mono- or di-saccharide together comprising from about 15% to about 60% of the core total weight and the weight ratio of the C.sub.6 sugar alcohol to said mono- or di saccharide is from about 1:9 to about 9:1;
(b) a semi-permeable wall around said core permeable to water or gastric fluid; and
(c) a hole through said semipermeable wall connecting said core with the external environment.
2. The delivery form of claim 1 wherein said active agent is present in an amount of from about 100 mg to about 400 mg, based on carbamazepine free base.
3. The delivery form of claim 1 wherein said crystal habit modifier is hydroxypropyl cellulose, said crystal habit modifier being present in an amount of about 9% to about 15% by weight based upon the amount said carbamazepine as free base.
4. The delivery form of claim 1 wherein said hydroxy-C.sub.1 -C.sub.4 alkyl celluloses are selected from different grades of the same hydroxy-C.sub.1 -C.sub.4 alkyl cellulose.
5. The delivery form of claim 4 wherein said hydroxy-C.sub.1 -C.sub.4 alkyl celluloses are selected from hydroxyethylcelluloses.
6. The delivery form of claim 5 wherein said hydroxyethyl cellulose grades are selected from 250H, 250L, 250J, 250E, 250G, 250K, 250M, 250MH, 250H4, and 250HH.
7. The delivery form of claim 1 wherein said C.sub.6 sugar alcohol is selected from mannitol, sorbitol and galactitol.
8. The delivery form of claim 7 wherein said C.sub.6 sugar alcohol is mannitol.
9. The delivery form of claim 1 wherein said mono- or di-saccharide is selected from glyceraldehyde, threose, erythrose, lyxose, xylose, arabinose, ribose, talose, galactose, idose, gulose, mannose, glucose, altrose, xylulose, tagatose, sorbose, psicose, hamamalose, allose, their corresponding ketoses and deoxy forms, pseudoheptulose, maltose, lactose, sucrose, cellobiose, isomaltose, and mixtures thereof.
10. The delivery form of claim 9 wherein said mono- or di-saccharide is dextrates N.F.
11. The delivery form of claim 1 wherein said tableting lubricant is magnesium stearate.
12. The delivery form of claim 1 wherein said wetting agent is sodium lauryl sulfate.
13. The delivery form of claim 1 further comprising a pharmaceutically acceptable coloring agent which is present in said core.
14. The delivery form of claim 1 wherein said semipermeable wall comprises at least one cellulose acetate, hydroxy-C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkyl cellulose, and a poly C.sub.2 -C.sub.4 alkylene glycol.
15. The delivery form of claim 14 wherein said polyC.sub.2 -C.sub.4 alkyleneglycol is polyethyleneglycol 8000.
16. The delivery form of claim 14 wherein said polyC.sub.2 -C.sub.4 alkyleneglycol is present in an amount of from about 6% to about 10% based on the total permeable wall weight.
17. The delivery form of claim 14 wherein said hydroxy-C.sub.1 -C.sub.4 alkyl C.sub.1 -C.sub.4 alkyl cellulose is present in an amount of from about 6% to 10% based on the total semipermeable wall weight.
18. The delivery form of claim 14 wherein said hydroxy-C.sub.1 -C.sub.4 alkyl C.sub.1 -C.sub.4 alkyl cellulose in said semipermeable wall is hydroxypropylmethyl cellulose.
19. The delivery form of claim 14 wherein said hydroxy-C.sub.1 -C.sub.4 alkyl C.sub.1 -C.sub.4 alkyl cellulose is a grade thereof having a viscosity of about 10-20 cps
20. The delivery form of claim 14 wherein said semipermeable wall comprises at least two different cellulose acetates.
21. The delivery form of claim 20 wherein said cellulose acetates are cellulose acetate 320S NF and cellulose acetate 398-10 NF and the radio of cellulose acetate 320S NF: cellulose acetate 398-10 NF is from about 5:1 to about 8:1.
22. The delivery form of claim 20 wherein the ratio of cellulose acetate 320S NF: cellulose acetate 398-10 NF is from about 6.62:1 to about 6.64:1.
23. The delivery form of claim 1 comprising
(a) a core of
in which the hydroxyethyl cellulose 250L:hydroxyethyl cellulose 250H ratio is from 1:4 to 4; and
(b) a semipermeable wall of
(c) a hole through said semipermeable wall connecting said core and the external environment.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.